Incidence of V600E Mutation in Patients with Papillary Thyroid Carcinoma: a Single-institution Experience

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2019 Sep 20

PMID 31533501

Citations 10

Authors

Shoko Kure

Kousuke Ishino

Mitsuhiro Kudo

Ryuichi Wada

Marie Saito

Ryuta Nagaoka

Iwao Sugitani

Zenya Naito

Affiliations

Soon will be listed here.

Citing Articles

Breaking barriers: noninvasive AI model for BRAF mutation identification.

Wu F, Lin X, Chen Y, Ge M, Pan T, Shi J Int J Comput Assist Radiol Surg. 2025; .

PMID: 39955452 DOI: 10.1007/s11548-024-03290-0.

BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.

Cong R, Ouyang H, Zhou D, Li X, Xia F World J Surg Oncol. 2024; 22(1):259.

PMID: 39342349 PMC: 11439211. DOI: 10.1186/s12957-024-03539-7.

Ultrasound features as predictive markers of mutation in thyroid cancer: a systematic review and meta-analysis.

Liu R, Li H, Bai X, Yang H, He Y Gland Surg. 2024; 13(7):1243-1253.

PMID: 39175707 PMC: 11336794. DOI: 10.21037/gs-24-134.

A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma.

Haghzad T, Khorsand B, Razavi S, Hedayati M Endocrine. 2024; 86(2):707-722.

PMID: 38886331 DOI: 10.1007/s12020-024-03911-3.

Younger Than 55 Years Old and V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm.

Lai Y, Gu Y, Yu M, Deng J Int J Gen Med. 2023; 16:1403-1414.

PMID: 37155469 PMC: 10122992. DOI: 10.2147/IJGM.S408588.

References

Malaguarnera R, Chen K, Kim T, Dominguez J, Voza F, Ouyang B . Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab. 2014; 99(10):E1976-87. PMC: 4184069. DOI: 10.1210/jc.2013-3976. View

Sakai T, Sugitani I, Ebina A, Fukuoka O, Toda K, Mitani H . Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma. Thyroid. 2018; 29(1):59-63. DOI: 10.1089/thy.2018.0462. View

Givens D, Buchmann L, Agarwal A, Grimmer J, Hunt J . BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope. 2014; 124(9):E389-93. DOI: 10.1002/lary.24668. View

Xu X, Quiros R, Gattuso P, Ain K, Prinz R . High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003; 63(15):4561-7. View

Oler G, Cerutti J . High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer. 2009; 115(5):972-80. DOI: 10.1002/cncr.24118. View

Henke L, Perkins S, Pfeifer J, Ma C, Chen Y, DeWees T . BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer. 2014; 61(7):1168-72. DOI: 10.1002/pbc.24935. View

Picarsic J, Buryk M, Ozolek J, Ranganathan S, Monaco S, Simons J . Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay. Pediatr Dev Pathol. 2015; 19(2):115-22. PMC: 5894824. DOI: 10.2350/15-07-1667-OA.1. View

Kim T, Kim W, Rhee Y, Song J, Kim J, Gong G . The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2006; 65(3):364-8. DOI: 10.1111/j.1365-2265.2006.02605.x. View

Bartolome A, Boskovic S, Paunovic I, Bozic V, Cvejic D . Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation. APMIS. 2016; 124(4):271-7. DOI: 10.1111/apm.12505. View

10.

Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K . KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol. 2017; 34(2):26. DOI: 10.1007/s12032-016-0879-9. View

11.

Vanden Borre P, Schrock A, Anderson P, Morris 3rd J, Heilmann A, Holmes O . Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Oncologist. 2017; 22(3):255-263. PMC: 5344643. DOI: 10.1634/theoncologist.2016-0279. View

12.

Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M . BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid. 2005; 15(4):320-5. DOI: 10.1089/thy.2005.15.320. View

13.

Oishi N, Kondo T, Nakazawa T, Mochizuki K, Inoue T, Kasai K . Frequent BRAF and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. Endocr Pathol. 2017; 28(2):103-111. DOI: 10.1007/s12022-017-9470-y. View

14.

Nikiforova M, Kimura E, Gandhi M, Biddinger P, Knauf J, Basolo F . BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11):5399-404. DOI: 10.1210/jc.2003-030838. View

15.

Lee S, Hwang T, Choi Y, Kim W, Han H, Lim S . Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF Mutation. Thyroid. 2017; 27(6):802-810. DOI: 10.1089/thy.2016.0547. View

16.

Ng J, Lu C, Lam A . BRAF mutation: Current and future clinical pathological applications in colorectal carcinoma. Histol Histopathol. 2018; 34(5):469-477. DOI: 10.14670/HH-18-079. View

17.

Malicherova B, Burjanivova T, Grendar M, Minarikova E, Bobrovska M, Vanova B . Droplet digital PCR for detection of mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas 4800, Sanger sequencing, and allele-specific PCR. Am J Transl Res. 2019; 10(11):3773-3781. PMC: 6291720. View

18.

Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A . In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF mutation. Virchows Arch. 2016; 469(6):687-696. DOI: 10.1007/s00428-016-2027-5. View

19.

Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas M, Nistal M, Santisteban P . The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006; 13(1):257-69. DOI: 10.1677/erc.1.01119. View

20.

Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View